Lixte Biotechnology Holdings (FRA:8640) Total Equity : €1.07 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Lixte Biotechnology Holdings Total Equity?

Lixte Biotechnology Holdings's total equity for the quarter that ended in Mar. 2025 was €1.07 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Lixte Biotechnology Holdings Total Equity Historical Data

The historical data trend for Lixte Biotechnology Holdings's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lixte Biotechnology Holdings Total Equity Chart

Lixte Biotechnology Holdings Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Equity

Get a 7-Day Free Trial

4.12

4.24

4.88

3.66

0.79

Lixte Biotechnology Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Equity	Get a 7-Day Free Trial															2.88	2.09	1.23	0.79	1.07

Lixte Biotechnology Holdings Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Lixte Biotechnology Holdings's Total Equity for the fiscal year that ended in Dec. 2024 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2024 )	-	Total Liabilities(Q: Dec. 2024 )
	=	1.094	-	0.304
	=	0.79

Lixte Biotechnology Holdings's Total Equity for the quarter that ended in Mar. 2025 is calculated as

Total Equity	=	Total Assets(Q: Mar. 2025 )	-	Total Liabilities(Q: Mar. 2025 )
	=	1.4	-	0.328
	=	1.07

Lixte Biotechnology Holdings Total Equity Related Terms

Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Lixte Biotechnology Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lixte Biotechnology Holdings Inc (FRA:8640) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

LIXT:USA

Address

680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101

Website

https://www.lixte.com

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Lixte Biotechnology Holdings Headlines

No Headlines